Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity

International Journal of Cancer

Volumn 136, Issue 9, 2015, Pages 2228-2240

  Fernández Ulibarri, Inés ^a   Hammer, Katharina ^a   Arndt, Michaela A E ^a   Kaufmann, Johanna K ^a,e   Dorer, Dominik ^a   Engelhardt, Sarah ^a   Kontermann, Roland E ^b   Hess, Jochen ^a,c   Allgayer, Heike ^a,d   Krauss, Jürgen ^a   Nettelbeck, Dirk M ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF STUTTGART   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

EGFR; ImmunoRNase; Oncolytic adenovirus; Onconase; ScFv

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOLYTIC ADENOVIRUS; RANPIRNASE; RITUXIMAB; RNA; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; ONCOLYTIC VIRUS; RIBONUCLEASE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SPECIFICITY; DRUG TOLERABILITY; FEMALE; GENE DELIVERY SYSTEM; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LUNG ADENOCARCINOMA; MELANOMA; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; RNA DEGRADATION; SQUAMOUS CELL CARCINOMA; TUMOR CELL DESTRUCTION; TUMOR XENOGRAFT; ADENOVIRIDAE; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; DRUG SCREENING; GENE THERAPY; GENE VECTOR; GENETICS; METABOLISM; PROCEDURES; TUMOR CELL LINE; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RIBONUCLEASES; RNA; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923167131     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29258     Document Type: Article

References (51)

1. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012;30: 658-70.
2. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded. Nat Rev Microbiol 2008;6: 529-40.
3. Kaufmann JK, Nettelbeck DM. Virus chimeras for gene therapy, vaccination, and oncolysis: Adenoviruses and beyond. Trends Mol Med 2012; 18: 365-76.
4. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006;5: 147-59.
5. Batra SK, Jain M, Wittel UA, et al. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 2002;13: 603-8.
6. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: Protein engineering strategies to improve exposure in solid tumors. Cancer 2007;109: 170-9.
7. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008;60: 1421-34.
8. Rybak SM, Arndt MA, Schirrmann T, et al. Ribonucleases and immunoRNases as anticancer drugs. Curr Pharm Des 2009;15: 2665-75.
9. Ardelt W, Ardelt B, Darzynkiewicz Z. Ribonucleases as potential modalities in anticancer therapy. Eur J Pharmacol 2009;625: 181-9.
10. Costanzi J, Sidransky D, Navon A, Goldsweig H. Ribonucleases as a novel pro-Apoptotic anticancer strategy: Review of the preclinical and clinical data for ranpirnase. Cancer Invest 2005;23: 643-50.
11. Newton DL, Hansen HJ, Mikulski SM, et al. Potent and specific antitumor effects of an anti-CD22-Targeted cytotoxic ribonuclease: Potential for the treatment of non-Hodgkin lymphoma. Blood 2001;97: 528-35.
12. Newton D, Pearson J, Xue Y, et al. Anti-Tumor ribonuclease, combined with or conjugated to monoclonal antibody MRK16, overcomes multidrug resistance to vincristine in vitro and in vivo. Int J Oncol 1996;8: 1095-104.
13. Chang CH, Sapra P, Vanama SS, et al. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 2005;106: 4308-14.
14. Chang CH, Gupta P, Michel R, et al. Ranpirnase (frog RNase) targeted with a humanized, internalizing, anti-Trop-2 antibody has potent cytotoxicity against diverse epithelial cancer cells. Mol Cancer Ther 2010;9: 2276-86.
15. Rybak SM. Antibody-onconase conjugates: Cytotoxicity and intracellular routing. Curr Pharm Biotechnol 2008;9: 226-30.
16. Schirrmann T, Krauss J, Arndt MA, et al. Targeted therapeutic RNases (ImmunoRNases). Expert Opin Biol Ther 2009;9: 79-95.
17. Kreitman RJ. Toxin-labeled monoclonal antibodies. Curr Pharm Biotechnol 2001;2: 313-25.
18. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005;23: 6719-29.
19. Messmann RA, Vitetta ES, Headlee D, et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(1), CD22(1) B cell lymphoma. Clin Cancer Res 2000;6: 1302-13.
20. Boix E, Wu Y, Vasandani VM, et al. Role of the N terminus in RNase A homologues: Differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity. J Mol Biol 1996;257: 992-1007.
21. Kim BM, Kim H, Raines RT, Lee Y. Glycosylation of onconase increases its conformational stability and toxicity for cancer cells. Biochem Biophys Res Commun 2004;315: 976-83.
22. Siegemund M, Pollak N, Seifert O, et al. Superior antitumoral activity of dimerized targeted singlechain TRAIL fusion proteins under retention of tumor selectivity. Cell Death Dis 2012;3: E295.
23. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1: 1311-8.
24. He X, Goldsmith CM, Marmary Y, et al. Systemic action of human growth hormone following adenovirus-mediated gene transfer to rat submandibular glands. Gene Ther 1998;5: 537-41.
25. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19: 2-12.
26. Rivera AA, Davydova J, Schierer S, et al. Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells. Gene Ther 2004; 11: 1694-702.
27. Quirin C, Rohmer S, Fernandez-Ulibarri I, et al. Selectivity and efficiency of late transgene expression by transcriptionally targeted oncolytic adenoviruses are dependent on the transgene insertion strategy. Hum Gene Ther 2011;22: 389-404.
28. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-Tumoral efficacy. Nat Med 2000;6: 1134-9.
29. Kawakami Y, Li H, Lam JT, et al. Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication. Cancer Res 2003;63: 1262-9.
30. Kim KH, Ryan MJ, Estep JE, et al. A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: The safety profile of ad5/3-Delta24 in advance of a phase I clinical trial in ovarian cancer patients. Hum Gene Ther 2011;22: 821-8.
31. Kanerva A, Nokisalmi P, Diaconu I, et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res 2013;19: 2734-44.
32. Cerullo V, Pesonen S, Diaconu I, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010;70: 4297-309.
33. Pesonen S, Diaconu I, Cerullo V, et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer 2012;130: 1937-47.
34. Koski A, Kangasniemi L, Escutenaire S, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010;18: 1874-84.
35. Kim KH, Dmitriev IP, Saddekni S, et al. A phase I clinical trial of Ad5/3-Delta24, a novel serotypechimeric, infectivity-enhanced, conditionallyreplicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol 2013;130: 518-24.
36. Liu X, Wu J, Zhang S, Li C, Huang Q. Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy. Cancer Gene Ther 2009;16: 861-72.
37. Liu X, Li J, Tian Y, et al. Enhanced pancreatic cancer gene therapy by combination of adenoviral vector expressing c-erb-B2 (Her-2/neu)-Targeted immunotoxin with a replication-competent adenovirus or etoposide. Hum Gene Ther 2010;21: 157-70.
38. Choi IK, Strauss R, Richter M, et al. Strategies to increase drug penetration in solid tumors. Front Oncol 2013;3: 193.
39. Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for treatment of glioblastoma: Molecular basis to overcome resistance. Curr Cancer Drug Targets 2012;12: 197-209.
40. Fecker LF, Schmude M, Jost S, et al. Efficient and selective tumor cell lysis and induction of apoptosis in melanoma cells by a conditional replication-competent CD95L adenovirus. Exp Dermatol 2010;19: E56-66.
41. Ketzer P, Haas SF, Engelhardt S, et al. Synthetic riboswitches for external regulation of genes transferred by replication-deficient and oncolytic adenoviruses. Nucleic Acids Res 2012;40: E167.
42. Chen H, Sampath P, Hou W, Thorne SH. Regulating cytokine function enhances safety and activity of genetic cancer therapies. Mol Ther 2013;21: 167-74.
43. Rohmer S, Mainka A, Knippertz I, et al. Insulated hsp70B' promoter: Stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses. J Gene Med 2008;10: 340-54.
44. Zielinski R, Lyakhov I, Jacobs A, et al. Affitoxin-A novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J Immunother 2009;32: 817-25.
45. Behdani M, Zeinali S, Karimipour M, et al. Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth. N Biotechnol 2013;30: 205-9.
46. Zahnd C, Kawe M, Stumpp MT, et al. Efficient tumor targeting with high-Affinity designed ankyrin repeat proteins: Effects of affinity and molecular size. Cancer Res 2010;70: 1595-605.
47. Rudnick SI, Lou J, Shaller CC, et al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res 2011;71: 2250-9.
48. Nakase I, Kobayashi S, Futaki S. Endosome-disruptive peptides for improving cytosolic delivery of bioactive macromolecules. Biopolymers 2010; 94: 763-70.
49. Arndt MA, Krauss J, Vu BK, et al. A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD221 tumor cells. J Immunother 2005;28: 245-51.
50. Krauss J, Arndt MA, Vu BK, et al. Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-Angiogenin immunoenzyme. Br J Haematol 2005;128: 602-9.
51. Menzel C, Schirrmann T, Konthur Z, et al. Human antibody RNase fusion protein targeting CD301 lymphomas. Blood 2008;111: 3830-7.